U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

Source: 
Reuters
snippet: 

A U.S. appeals court on Friday ruled invalid patents owned by Jazz Pharmaceuticals PLC covering its narcolepsy drug Xyrem, giving Amneal Pharmaceuticals Inc a boost in its effort to launch a generic version of the medicine.